Incidence and Clinical Practice of Myopic Macular Neovascularization: A Nationwide Population-Based Cohort Study
Purpose: To elucidate the epidemiological background of myopic macular neovascularization (mMNV), including its incidence and treatment patterns. Design: A population-based cohort study using a nationwide claims database. Participants: Individuals covered by the Japanese National Health Insurance Sy...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-11-01
|
| Series: | Ophthalmology Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666914525001320 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850117702629195776 |
|---|---|
| author | Masahiro Akada, MD Masahiro Miyake, PhD, MPH Masayuki Hata, MD, PhD Ai Kido, MD, PhD Wakako Okayama, MD Ai Nakata, MD Shinya Nakao, MD Kazuya Morino, MD Shota Yasukura, MD Yuki Mori, MD, PhD Hiroshi Tamura, PhD, ScM Akitaka Tsujikawa, MD, PhD |
| author_facet | Masahiro Akada, MD Masahiro Miyake, PhD, MPH Masayuki Hata, MD, PhD Ai Kido, MD, PhD Wakako Okayama, MD Ai Nakata, MD Shinya Nakao, MD Kazuya Morino, MD Shota Yasukura, MD Yuki Mori, MD, PhD Hiroshi Tamura, PhD, ScM Akitaka Tsujikawa, MD, PhD |
| author_sort | Masahiro Akada, MD |
| collection | DOAJ |
| description | Purpose: To elucidate the epidemiological background of myopic macular neovascularization (mMNV), including its incidence and treatment patterns. Design: A population-based cohort study using a nationwide claims database. Participants: Individuals covered by the Japanese National Health Insurance System between 2016 and 2022. Methods: This study utilized data from the national claims database managed by the Japan Ministry of Health, Labour and Welfare. The database covers over 95% of health care claims in Japan under the universal health coverage system. We identified individuals with new-onset mMNV between January 2016 and December 2022. We also calculated incidence rates based on age and sex stratification for each year. We also assessed the initial treatment patterns for mMNV, focusing on the use of anti-VEGF therapy. Main Outcome Measures: Incidence rates and treatment patterns of mMNV. Results: During the 7-year period, we identified 45 671 cases of mMNV, with 70.7% occurring in women. The crude incidence rate (per 100 000 person-years) in the general population was 5.17 (95% confidence interval [CI], 5.13–5.22), with 3.12 (95% CI, 3.07–3.18) in men and 7.12 (95% CI, 7.04–7.19) in women. The mean age of onset was lower in men (59.3 ± 16.7 years) than in women (63.5 ± 16.2 years). In total, 52.6% of newly diagnosed patients with mMNV received anti-VEGF treatment, with 43.5% receiving ranibizumab and 56.5% receiving aflibercept. The number of injections in the first (0–12 months), second (13–24 months), and third (25–36 months) years after the initial injection was 2.45 ± 1.83, 0.62 ± 1.42, and 0.46 ± 1.27, respectively. Conclusions: This study provides the largest population-based evidence on the detailed epidemiology of mMNV following the implementation of anti-VEGF therapy under the Japanese National Insurance System. We examined how the incidence varied over time and analyzed the usage rates of each anti-VEGF agent, as well as the number of injections, offering valuable insights into the medical and social implications of mMNV following the widespread implementation of anti-VEGF therapy. These findings enhance understanding of the medical and social features of mMNV. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. |
| format | Article |
| id | doaj-art-d7983297754645d08f0bbdcb7c7a06f4 |
| institution | OA Journals |
| issn | 2666-9145 |
| language | English |
| publishDate | 2025-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Ophthalmology Science |
| spelling | doaj-art-d7983297754645d08f0bbdcb7c7a06f42025-08-20T02:36:02ZengElsevierOphthalmology Science2666-91452025-11-015610083410.1016/j.xops.2025.100834Incidence and Clinical Practice of Myopic Macular Neovascularization: A Nationwide Population-Based Cohort StudyMasahiro Akada, MD0Masahiro Miyake, PhD, MPH1Masayuki Hata, MD, PhD2Ai Kido, MD, PhD3Wakako Okayama, MD4Ai Nakata, MD5Shinya Nakao, MD6Kazuya Morino, MD7Shota Yasukura, MD8Yuki Mori, MD, PhD9Hiroshi Tamura, PhD, ScM10Akitaka Tsujikawa, MD, PhD11Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, JapanDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan; Correspondence: Masahiro Miyake, PhD, MPH, Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin, Kawahara, Sakyo, Kyoto 606-8507, Japan.Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, JapanDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan; Department of Ophthalmology, Kyoto Okamoto Memorial Hospital, Kyoto, JapanDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, JapanDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, JapanDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, JapanDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, JapanDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, JapanDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, JapanDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan; Center for Innovative Research and Education in Data Science, Institute for Liberal Arts and Sciences, Kyoto University, Kyoto, JapanDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, JapanPurpose: To elucidate the epidemiological background of myopic macular neovascularization (mMNV), including its incidence and treatment patterns. Design: A population-based cohort study using a nationwide claims database. Participants: Individuals covered by the Japanese National Health Insurance System between 2016 and 2022. Methods: This study utilized data from the national claims database managed by the Japan Ministry of Health, Labour and Welfare. The database covers over 95% of health care claims in Japan under the universal health coverage system. We identified individuals with new-onset mMNV between January 2016 and December 2022. We also calculated incidence rates based on age and sex stratification for each year. We also assessed the initial treatment patterns for mMNV, focusing on the use of anti-VEGF therapy. Main Outcome Measures: Incidence rates and treatment patterns of mMNV. Results: During the 7-year period, we identified 45 671 cases of mMNV, with 70.7% occurring in women. The crude incidence rate (per 100 000 person-years) in the general population was 5.17 (95% confidence interval [CI], 5.13–5.22), with 3.12 (95% CI, 3.07–3.18) in men and 7.12 (95% CI, 7.04–7.19) in women. The mean age of onset was lower in men (59.3 ± 16.7 years) than in women (63.5 ± 16.2 years). In total, 52.6% of newly diagnosed patients with mMNV received anti-VEGF treatment, with 43.5% receiving ranibizumab and 56.5% receiving aflibercept. The number of injections in the first (0–12 months), second (13–24 months), and third (25–36 months) years after the initial injection was 2.45 ± 1.83, 0.62 ± 1.42, and 0.46 ± 1.27, respectively. Conclusions: This study provides the largest population-based evidence on the detailed epidemiology of mMNV following the implementation of anti-VEGF therapy under the Japanese National Insurance System. We examined how the incidence varied over time and analyzed the usage rates of each anti-VEGF agent, as well as the number of injections, offering valuable insights into the medical and social implications of mMNV following the widespread implementation of anti-VEGF therapy. These findings enhance understanding of the medical and social features of mMNV. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.http://www.sciencedirect.com/science/article/pii/S2666914525001320MyopiaMyopic macular neovascularizationAnti-VEGFRanibizumabAflibercept |
| spellingShingle | Masahiro Akada, MD Masahiro Miyake, PhD, MPH Masayuki Hata, MD, PhD Ai Kido, MD, PhD Wakako Okayama, MD Ai Nakata, MD Shinya Nakao, MD Kazuya Morino, MD Shota Yasukura, MD Yuki Mori, MD, PhD Hiroshi Tamura, PhD, ScM Akitaka Tsujikawa, MD, PhD Incidence and Clinical Practice of Myopic Macular Neovascularization: A Nationwide Population-Based Cohort Study Ophthalmology Science Myopia Myopic macular neovascularization Anti-VEGF Ranibizumab Aflibercept |
| title | Incidence and Clinical Practice of Myopic Macular Neovascularization: A Nationwide Population-Based Cohort Study |
| title_full | Incidence and Clinical Practice of Myopic Macular Neovascularization: A Nationwide Population-Based Cohort Study |
| title_fullStr | Incidence and Clinical Practice of Myopic Macular Neovascularization: A Nationwide Population-Based Cohort Study |
| title_full_unstemmed | Incidence and Clinical Practice of Myopic Macular Neovascularization: A Nationwide Population-Based Cohort Study |
| title_short | Incidence and Clinical Practice of Myopic Macular Neovascularization: A Nationwide Population-Based Cohort Study |
| title_sort | incidence and clinical practice of myopic macular neovascularization a nationwide population based cohort study |
| topic | Myopia Myopic macular neovascularization Anti-VEGF Ranibizumab Aflibercept |
| url | http://www.sciencedirect.com/science/article/pii/S2666914525001320 |
| work_keys_str_mv | AT masahiroakadamd incidenceandclinicalpracticeofmyopicmacularneovascularizationanationwidepopulationbasedcohortstudy AT masahiromiyakephdmph incidenceandclinicalpracticeofmyopicmacularneovascularizationanationwidepopulationbasedcohortstudy AT masayukihatamdphd incidenceandclinicalpracticeofmyopicmacularneovascularizationanationwidepopulationbasedcohortstudy AT aikidomdphd incidenceandclinicalpracticeofmyopicmacularneovascularizationanationwidepopulationbasedcohortstudy AT wakakookayamamd incidenceandclinicalpracticeofmyopicmacularneovascularizationanationwidepopulationbasedcohortstudy AT ainakatamd incidenceandclinicalpracticeofmyopicmacularneovascularizationanationwidepopulationbasedcohortstudy AT shinyanakaomd incidenceandclinicalpracticeofmyopicmacularneovascularizationanationwidepopulationbasedcohortstudy AT kazuyamorinomd incidenceandclinicalpracticeofmyopicmacularneovascularizationanationwidepopulationbasedcohortstudy AT shotayasukuramd incidenceandclinicalpracticeofmyopicmacularneovascularizationanationwidepopulationbasedcohortstudy AT yukimorimdphd incidenceandclinicalpracticeofmyopicmacularneovascularizationanationwidepopulationbasedcohortstudy AT hiroshitamuraphdscm incidenceandclinicalpracticeofmyopicmacularneovascularizationanationwidepopulationbasedcohortstudy AT akitakatsujikawamdphd incidenceandclinicalpracticeofmyopicmacularneovascularizationanationwidepopulationbasedcohortstudy |